ArticleNeuro-oncology advances
Exploring brain-glioma interaction: Effect of neuroligin-3 expression on neurocognitive functioning is independent from epilepsy.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neurocognitive deficits are common in patients with diffuse glioma, compromising quality of life and prognosis. Neuroligin-3 is a postsynaptic activity-dependent protein, considered a key component of brain-glioma interactions, specifically at neurogliomal synapses. Neuroligin-3 may modulate neuronal and epileptic activity, contributing to both tumor growth and cognitive deficits. We aimed to investigate the relationship between intratumoral neuroligin-3 expression and neurocognitive functioning (NCF) in diffuse glioma patients, and to determine whether epilepsy modifies this relationship. Methods: In this single-center retrospective study, adult patients with grades 2-4 diffuse glioma underwent neuropsychological assessment prior to awake surgery. Tissue microarray analysis was used to assess intratumoral neuroligin-3 expression. We examined the relation between NCF (attention and executive functioning, memory, language, visuospatial functioning and psychomotor speed) and neuroligin-3 expression, using multivariable logistic regression models adjusting for tumor grade, location and volume. Additionally, presence of epilepsy and its interaction term with neuroligin-3 expression were added to separate models. Results: In total, 101 patients were included for analyses. Neuroligin-3 showed a protective effect on memory performance in all patients, not modified by epilepsy. Patients with neuroligin-3-positive high-grade and isocitrate dehydrogenase (IDH)-wild type glioma have a decreased risk of memory and attention and executive functioning deficits, again not modified by epilepsy. In low-grade and IDH-mutant glioma patients, neuroligin-3 expression was not associated with NCF. Conclusions: Intratumoral neuroligin-3 expression is an independent determinant of NCF, especially in the domain memory and in high-grade and IDH-wild type glioma. This protective effect was not modified by presence of epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.